Drug Trial Radar · NCT07839819
Study of PM54 in Combination With Cytotoxic and Targeted Agents in Adult Participants With Advanced Malignancies
Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
231
Planned (sponsor's estimate)
Start
Nov 12, 2026
Primary completion
Sep 27, 2029
Study completion Nov 27, 2029
Sponsor
- Lead sponsor
- PharmaMarIndustry
- Sponsor type
- Industry
- First posted
- Sep 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the safety, tolerability and recommended dose (RD) of PM54 in combination with cytotoxic and targeted anticancer agents in adult participants with advanced solid tumors. The study will also assess the antitumor activity of PM54 in combination with cytotoxic and targeted anticancer agents in terms of objective response rate (ORR) based on investigator's assessment in participants in other cohorts.
Conditions
- Advanced Solid Tumor
Interventions
PM54Drug
Intravenous infusion.
IrinotecanDrug
Intravenous infusion.
DoxorubicinDrug
Intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parts 1 and 2: Number of Participants with Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Leading to Treatment Discontinuation or Dose ModificationsTime frame: Time from the first administration of study intervention until 30 days after study intervention discontinuation or initiation of new subsequent anticancer therapy, whichever occurs first (up to 5 years)
- Part 1: Number of Participants with Dose-Limiting Toxicities (DLTs)Time frame: Cycle 1 (each cycle is of 21 days)
- Part 2: Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1Time frame: Baseline up to 5 years
Locations
9 sites in 4 countries. Site status is shown where the registry gives one.
University of Nebraska Medical Center
Omaha, Nebraska
The University of Texas MD Anderson Cancer Center
Houston, Texas
Institut Bergonie
Bordeaux, France
Centre Leon Berard - Lyon
Lyon, France
Centre Antoine Lacassagne
Nice, France
Helios Klinikum Berlin-Buch
Buckow, Germany
Universitaetsmedizin Mainz
Mainz, Germany
START Lisbon - ULS Santa Maria
Lisbon, Portugal
Instituto Portugues De Oncologia Do Porto Francisco Gentil Epe Ipo Porto Ipopfg Clinica De Onco Hematologia
Porto, Portugal
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.